Fjarde AP Fonden Fourth Swedish National Pension Fund Trims Holdings in Kenvue Inc. $KVUE

Fjarde AP Fonden Fourth Swedish National Pension Fund trimmed its position in Kenvue Inc. (NYSE:KVUE) by 12.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 263,135 shares of the company’s stock after selling 36,400 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Kenvue were worth $4,539,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of KVUE. Norges Bank purchased a new position in shares of Kenvue in the fourth quarter worth about $756,862,000. Van ECK Associates Corp raised its stake in shares of Kenvue by 101.3% in the third quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock worth $298,008,000 after purchasing an additional 9,240,434 shares during the last quarter. American Century Companies Inc. raised its stake in shares of Kenvue by 22.4% in the third quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock worth $601,267,000 after purchasing an additional 6,781,640 shares during the last quarter. Bessemer Group Inc. raised its stake in shares of Kenvue by 156.2% in the fourth quarter. Bessemer Group Inc. now owns 8,491,343 shares of the company’s stock worth $146,475,000 after purchasing an additional 5,177,404 shares during the last quarter. Finally, Mondrian Investment Partners LTD purchased a new position in shares of Kenvue in the third quarter worth about $79,269,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Down 0.9%

Kenvue stock opened at $17.56 on Tuesday. The firm has a market cap of $33.71 billion, a price-to-earnings ratio of 20.65, a price-to-earnings-growth ratio of 1.34 and a beta of 0.54. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $22.87. The business’s 50-day moving average price is $17.37 and its 200 day moving average price is $17.49. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.Kenvue’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period last year, the company earned $0.24 earnings per share. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.7%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is 97.65%.

Insider Buying and Selling

In related news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.59% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on KVUE. Barclays reduced their price objective on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 14th. Weiss Ratings cut Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. Argus upgraded Kenvue to a “hold” rating in a research note on Friday, March 6th. Zacks Research raised Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Finally, Citigroup dropped their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have issued a Hold rating to the company. Based on data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average price target of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.